the SmallCapReview mailing list.
Aurinia Pharmaceuticals: A
late-stage biopharmaceutical company providing novel products specifically
engineered to treat a limited, targeted patient population suffering from
serious disease states for which there is a high unmet medical need.
Myriad Genetics: A
personalized medicine company, that focuses on the
development and marketing of predictive, personalized, and
prognostic medicine tests worldwide.
MYGN has a collaboration with AstraZeneca for the
development of an indication for BRACAnalysis CDx.
Where Small Cap Stocks Thrive Since
Small Cap Stocks, A Recovery Is Taking Place
Cap ETFs Look To Rally
Cap Leaders For A Rough October
Cap Stocks Raise Hope That Selling Is Over Small-caps
are seeing relative strength.
About The Stock Markets Decline? Junk Bonds Aren't
Market Pullback Brings Out The Buyers
Presents Progression Free Survival In Prostrate Cancer Patients
cancer is the second most frequently diagnosed cancer in men.
ETF Betting On Small Cap Stocks Leaves Pros In The Dust
Sell Off Nearly Over And Will Be Reversed
the S&P 500 and the Russell 2000, which tracks small-cap stocks, hit
"extremely oversold" levels last week, according to the
Dividends In Small Caps
Small Caps For October
Caps And Renewed Strength For Cyclicals
Caps To Watch
Cap IR By The Numbers Average
Small Cap IR budget: $224,000, with $78,000 spent on external services.
has the potential to become a best in class medication and the first
approved treatment for LN in the U.S. and Europe."
on AUPH here...
has the deepest diagnostic pipeline across the disease spectrum."
on MYGN here...
Subscribers to our Free
newsletter will receive stock reports and news alerts for small-cap stocks
via email. You can sign-up
"A Primer In
is a leading destination for small-cap picks and news. The Purpose of
is to profile and bring awareness to companies with a market cap of
less than $1 billion, these small-cap stocks will primarily trade on the Nasdaq Small-Cap market. We also issue daily small cap
stocks to watch via various newswires. We will strive to bring you the
undiscovered, the undervalued, and the oversold.
does not give "buy" recommendations, price targets nor
suggest entry and exit points.
"A Look at Small Cap Stocks that may no longer be Small Caps"